"Erlotinib Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.
| Descriptor ID |
D000069347
|
| MeSH Number(s) |
D03.633.100.786.375
|
| Concept/Terms |
CP 358774- CP 358774
- 358774, CP
- CP 358,774
- 358,774, CP
- CP-358,774
- CP358,774
- CP-358774
- CP358774
Erlotinib- Erlotinib
- N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
|
Below are MeSH descriptors whose meaning is more general than "Erlotinib Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Erlotinib Hydrochloride".
This graph shows the total number of publications written about "Erlotinib Hydrochloride" by people in this website by year, and whether "Erlotinib Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 2 | 2 | 4 |
| 2017 | 7 | 8 | 15 |
| 2018 | 8 | 5 | 13 |
| 2019 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Erlotinib Hydrochloride" by people in Profiles.
-
In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression. Mol Syst Biol. 2020 07; 16(7):e9628.
-
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. Eur J Cancer. 2019 09; 119:77-86.
-
Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential. Int J Biol Macromol. 2019 Oct 15; 139:1304-1316.
-
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 06 01; 144(11):2887-2896.
-
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nat Commun. 2018 11 21; 9(1):4904.
-
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET. Clin Lung Cancer. 2019 03; 20(2):e148-e151.
-
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opin Pharmacother. 2018 12; 19(18):2055-2062.
-
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs). Eur J Radiol. 2018 Dec; 109:130-135.
-
Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells. Cell Physiol Biochem. 2018; 49(4):1615-1632.
-
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncol. 2018 09 01; 4(9):1189-1197.